Robert SussmanPresident, East Coast Operations SafeBridge
Allan ClarkeDirector, Process Formulation and Analysis GSK
Farrah ChaudharyContract Manufacturing Project Manager ImmunoGen
Jennifer WrightAssociate Director EHS Biogen Idec
HPAPI 2013 is the must-attend meeting for drug developers and CMOs working with HPAPIs. This is the meeting where you will find world class information and guidance on how to improve on your commercial success, whilst ensuring that your safety, containment and handling strategies and systems are airtight and future-proof.
A world class speaker line-up from the likes of Johnson & Johnson, ImmunoGen, Novasep, SafeBridge, AbbVie, GSK, Merck and Biogen Idec will help you crack vital issues like:
This meeting brings anyone working with HPAPIs together, under one roof. An unbeatable networking schedule gives you unrivalled access to knowledge from the leading minds in highly potent drug development and manufacturing.
Over 8 hours of dedicated networking time over 3 days, Speed Networking and highly interactive workshops, panel sessions and discussion groups with people who face many of the same challenges you do. Share expertise, successes and failures, and get real solutions.
Leave this meeting with all of the tools and practical solutions you need to:
Search groups for HPAPIs Forum to meet attendees, speakers and others working in the field of HPAPIs.
“That was the best event I have ever attended. I don’t usually consider commercial events but that was very good. You have a committed customer from this point onwards.” Sanofi Aventis
“Very valuable and useful information. One of the best meetings I’ve ever attended.” Millenium
“It exceeded my expectations. The talks were high quality and the interaction among participants was excellent.” Genentech
“A great place to get the latest information and networking.” Pfizer
“Strong program, great speakers and a genuine focus on identifying solutions.” Novartis
“An excellent opportunity to find out what other Pharma are doing and what’s emerging. Very valuable.” AstraZeneca